Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph G Wettstein

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Handbook of Experimental Pharmacology|May 16, 2015
Closing thoughts for cognitive enhancementKathleen M Kantak, Joseph G Wettstein
Neuroscience Letters|July 24, 2003
Delayed treatment with 5-nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione, a glycine site N-methyl-D-aspartate antagonist, protects against permanent middle cerebral artery occlusion in male ratsShakir Sarhan, Joseph G Wettstein, Kenneth I Maynard
Current Opinion in Pharmacology|December 10, 2014
Metabotropic glutamate receptor 5 as drug target for Fragile X syndromeSebastian H Scharf, Georg Jaeschke, Joseph G Wettstein, et al.
Nature Reviews. Neuroscience|July 16, 2010
Sleep and circadian rhythm disruption in psychiatric and neurodegenerative diseaseKatharina Wulff, Silvia Gatti, Joseph G Wettstein, et al.
Molecular Pharmacology|June 23, 2009
Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonistsPari Malherbe, Edilio Borroni, Emmanuel Pinard, et al.
Schizophrenia Research|May 6, 2003
Comparative analysis of acute and chronic administration of haloperidol and clozapine using [3H] 2-deoxyglucose metabolic mappingJill Wotanis, Susan E Hanak, Joseph G Wettstein, et al.
Pharmacology, Biochemistry, and Behavior|August 4, 2010
Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potentialDaniela Alberati, Jean-Luc Moreau, Roland Mory, et al.
Molecular Pharmacology|April 21, 2010
Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA)Pari Malherbe, Olivier Roche, Anne Marcuz, et al.
Neuroscience and Biobehavioral Reviews|May 12, 2009
Rodent models of insomnia: a review of experimental procedures that induce sleep disturbancesFlorent G Revel, Juergen Gottowik, Sylvia Gatti, et al.
Journal of Biopharmaceutical Statistics|March 15, 2003
Statistical method for analysis of the disease curve in animals with experimental autoimmune encephalomyelitisYonghee Lee, Bin Zhu, Claudine Pulicicchio, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Handbook of Experimental Pharmacology|May 16, 2015
Closing thoughts for cognitive enhancementKathleen M Kantak, Joseph G Wettstein
Neuroscience Letters|July 24, 2003
Delayed treatment with 5-nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione, a glycine site N-methyl-D-aspartate antagonist, protects against permanent middle cerebral artery occlusion in male ratsShakir Sarhan, Joseph G Wettstein, Kenneth I Maynard
Current Opinion in Pharmacology|December 10, 2014
Metabotropic glutamate receptor 5 as drug target for Fragile X syndromeSebastian H Scharf, Georg Jaeschke, Joseph G Wettstein, et al.
Nature Reviews. Neuroscience|July 16, 2010
Sleep and circadian rhythm disruption in psychiatric and neurodegenerative diseaseKatharina Wulff, Silvia Gatti, Joseph G Wettstein, et al.
Molecular Pharmacology|June 23, 2009
Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonistsPari Malherbe, Edilio Borroni, Emmanuel Pinard, et al.
Schizophrenia Research|May 6, 2003
Comparative analysis of acute and chronic administration of haloperidol and clozapine using [3H] 2-deoxyglucose metabolic mappingJill Wotanis, Susan E Hanak, Joseph G Wettstein, et al.
Pharmacology, Biochemistry, and Behavior|August 4, 2010
Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potentialDaniela Alberati, Jean-Luc Moreau, Roland Mory, et al.
Molecular Pharmacology|April 21, 2010
Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA)Pari Malherbe, Olivier Roche, Anne Marcuz, et al.
Neuroscience and Biobehavioral Reviews|May 12, 2009
Rodent models of insomnia: a review of experimental procedures that induce sleep disturbancesFlorent G Revel, Juergen Gottowik, Sylvia Gatti, et al.
Journal of Biopharmaceutical Statistics|March 15, 2003
Statistical method for analysis of the disease curve in animals with experimental autoimmune encephalomyelitisYonghee Lee, Bin Zhu, Claudine Pulicicchio, et al.
Pageof 5